Conveners
Cancer & therapies: Part A
- Ali Mahdipour-Shirayeh ()
Cancer & therapies: Part B
- Angela Jarrett (University of Texas at Austin)
In this paper, a mathematical model of breast cancer governed by a system of ordinary differential equations in the presence of chemotherapy treatment and ketogenic diet is discussed. Several comprehensive mathematical analysis was carried out using varieties of analytical methods to study the stability of the breast cancer model. Also, sufficient conditions on parameter values to ensure...
The advances in cell imaging technology has allowed for deeper understanding of the movement mechanisms of immune cells. Experimental evidence suggests that cytotoxic T lymphocytes and dendritic cells undergo and unrestricted search motion until they switch to a more restricted motion induced by activation by tumour antigens. This change in movement is not often considered in the existing...
Clinical methods for assessing tumour response to neoadjuvant therapy largely rely on monitoring the temporal changes in tumour size. Our goal is to predict tumour response to neoadjuvant therapy in breast cancer using a mathematical model that utilizes non-invasive imaging data obtained from individual patients. Previously, a mechanically-coupled, reaction-diffusion model with logistic growth...
It is becoming increasingly clear that tumour cells recruit cells in their surrounding microenvironment to aid in their proliferation. Tumour-associated macrophages and stromal cells are now believed to play a prominent role in tumour growth. Some evidence points to the fact that iron is a key player in the complex interactions between cancer cells and the microenvironment. This talk will...
Heterogeneity in cancer is increasingly being recognized as a key determinant of tumour progression and response to therapy. However, much of our current understanding of this heterogeneity has been driven by our ability to measure it, and therefore has largely focused on the genomic scale. Ultimately such heterogeneity is realized through the generation of distinct phenotypes. In recent years...
Accurate clinical assessment of a patient's response to treatment is a critical task in the era of precision medicine. Glioblastoma (GBM), a primary brain tumour with dismal median survival times of 12-16 months, has a highly heterogeneous, invasive profile, causing tumour dynamics and therapeutic response to vary widely from patient to patient. Currently, two sets of standard assessment...
Residual premalignant lesions after the first treatment such as surgery and chemotherapy are considered to be a cause of cancer recurrence. A previous study showed that the presence of premalignant lesions surrounding the primary tumour drives the high rate of local cancer recurrence. If cancerization requires m specific mutations in one cell, cells which have less than m mutations are still...
Introduction. Radiation therapy is a critical portion of the standard-of-care for patients with brain tumours, as it targets residual disease and non-operable tumours. However, one of the shortcomings of radiation therapy is the heterogeneity of response observed in the patient population which may be due to fundamental limitations in the way radiation therapy plans are currently selected....
Rapidly dividing tissues, like intestinal crypts, are frequently chosen to investigate the process of tumour initiation, because of their high rate of mutations. To study the interplay between normal and mutant as well as immortal cells in the human colon or intestinal crypt, we developed a 4-compartmental stochastic model for cell dynamics based on current discoveries. Recent studies of the...